GlassScriptPhysician profile
James G Fox
NPI 1962602789
$5,830.44
in general payments reported to CMS, 2019-2025
34 companies · $593 in 2025
The $593 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $76.67 · 2020: $101 · 2021: $326 · 2022: $509 · 2023: $3,482 · 2024: $743 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $3,107 · Food and Beverage: $1,711.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $3,107.21 |
| Food and Beverage | $1,710.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,000.00 | 2023 | Ion |
| Glaxosmithkline, LLC. | $1,101.75 | 2020-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.48 | 2021-2024 | Ofev |
| Astrazeneca Pharmaceuticals LP | $177.62 | 2020-2025 | Airsupra, Breztri, Tagrisso |
| Genzyme Corporation | $125.36 | 2021-2025 | |
| Actelion Pharmaceuticals US, INC. | $117.10 | 2024-2025 | Opsumit, Uptravi |
| Ethicon US, LLC | $112.59 | 2023-2024 | Enseal, Echelon Flex, Ethicon |
| Takeda Pharmaceuticals U.S.A., INC. | $111.43 | 2021-2025 | Glassia |
| Paratek Pharmaceuticals, INC. | $84.13 | 2023-2025 | Nuzyra |
| Merck Sharp & Dohme LLC | $81.13 | 2021-2025 | Capvaxive, Pifeltro, Zerbaxa |
| Sunovion Pharmaceuticals INC. | $79.54 | 2019-2020 | |
| Pfizer INC. | $66.41 | 2020-2021 | |
| Electromed, INC. | $51.11 | 2024-2025 | Smartvest |
| Grifols USA, LLC | $49.28 | 2024 | Prolastin-C Liquid |
| Genentech USA, INC. | $44.51 | 2021-2023 | Xolair, Actemra |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $38.40 | 2024 | Illumisite |
| Tactile Systems Technology INC | $31.75 | 2022 | |
| Abiomed | $30.78 | 2024 | Impella |
| Mylan Specialty L.P. | $30.09 | 2019-2023 | Yupelri |
| Beckman Coulter, INC. | $27.11 | 2024 | |
| Ani Pharmaceuticals, INC. | $25.22 | 2024 | Purified Cortrophin Gel |
| Regeneron Healthcare Solutions, INC. | $24.20 | 2025 | Dupixent |
| Viatris Specialty LLC | $23.54 | 2025 | Yupelri |
| United Therapeutics Corporation | $21.39 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $19.53 | 2021 | |
| Hospira, INC. | $18.47 | 2025 | |
| Pharming Healthcare, INC. | $18.33 | 2024 | Ruconest |
| Inogen, INC. | $18.28 | 2024 | |
| Insmed, INC. | $17.95 | 2025 | Arikayce |
| Inspire Medical Systems, INC. | $16.90 | 2024 | Inspire |
| Amgen INC. | $16.51 | 2025 | Tezspire |
| Abbvie INC. | $14.19 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.14 | 2024 | Xarelto |
| Btg International INC. | $7.22 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Fox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.